A

argenx

Develops antibody-based therapies for autoimmune diseases

Medical Affairs and Evidence Generation Asset Lead Executive Director

Biology & BiotechConfirmed live in the last 24 hours
Full-timeNo salary listed

About the Job

Requirements

  • An advanced degree in a scientific specialty (MD, PhD, PharmD, or equivalent) is required.
  • At least 15 years of nephrology clinical practice, nephrology research, and/or nephrology biopharmaceutical industry experience.
  • Experience designing, conducting, and interpreting clinical trials.
  • Ability to develop and maintain a high level of knowledge in complex disease areas, treatments, and clinical development plans.
  • Ability to accurately and effectively evaluate and interpret medical and scientific literature and the evolving treatment landscape to develop effective medical affairs strategies and meet or exceed targeted objectives.
  • Ability to prepare, adapt, and deliver presentations and complex data, and to engage with and influence diverse stakeholders.
  • Ability to work in a complex, fast-moving, matrixed environment and lead teams through ambiguity; manage competing demands and priorities; balance short- and long-term goals; adapt approach to circumstances; and handle change, delays, or unexpected events.
  • Ability to collaborate and co-create across functions and seek input from stakeholders across multiple geographies.
  • Ability to balance team and individual responsibilities, give and receive feedback, contribute to team success, and coach and develop people.
  • Strong problem-solving skills and a proactive, solution-oriented approach, including developing options through innovative thinking.
  • Detailed understanding of regulations and practices related to industry interactions with healthcare professionals and product access.
  • Ability to travel 30–40% as needed, domestically and globally, and spend some time in argenx offices.

Responsibilities

  • Serve as the MA&EG lead on the ARGX-121 Asset Strategy Team, providing strategic guidance based on deep insights and input from regional and country MA&EG teams to guide clinical asset development and lifecycle management, including identifying new indications based on disease biology and mechanism to maximize patient outcomes and access.
  • Work with ARGX-121 Science, Clinical Development, MA&EG, and Commercial teams to execute lifecycle deliverables from development through commercialization, including providing input on clinical trial protocols and study-site selection and partnering with the clinical study team to troubleshoot study issues.
  • Develop and execute Integrated Evidence Generation Plans throughout the product lifecycle.
  • Lead the ARGX-121 MA&EG community and partner with colleagues to develop and execute medical strategies through scientific communications and publications, advisory boards, medical information, congress activities, medical field content development, and data-generation activities; regularly communicate the asset development strategy and plans to the community.
  • As the molecule progresses in development, hire and manage indication leads.
  • As a member of the MA&EG Leadership Team, co-create and help drive MA&EG strategies aligned with argenx Vision 2030 and its expansion across indications, molecules, and patient impact.
  • Foster an inclusive and collaborative team environment that supports innovative solutions and strategies, flexibility, and effective work.
  • Ensure medical affairs activities comply with applicable pharmaceutical regulations and argenx policies and procedures.
  • Represent the totality of MA&EG activities, insights, and deliverables on the argenx Asset Strategy Team and related cross-functional teams, and provide strategic insights to maximize patient benefit.

Desired Qualifications

  • At least 5 years of medical affairs industry experience is strongly preferred.
  • Knowledge of drug development, rare disease experience, and an existing expert network are advantageous.

About the Company

argenx

Develops antibody-based therapies for autoimmune diseases

Argenx develops and markets antibody-based therapies for severe autoimmune diseases, turning immunology research into medicines. Its lead drug, efgartigimod (VYVGART), and the subcutaneous VYVGART Hytrulo treat conditions like generalized myasthenia gravis and CIDP by modulating the immune system through FcRn pathways. The company differentiates itself with antibody engineering and a co-creation model with academic and industry partners, plus a pipeline targeting FcRn-, complement-, and other autoimmune pathways and a global development footprint. Its goal is to provide effective antibody medicines for autoimmune diseases and broaden global patient access.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Amsterdam, Netherlands
Founded
2008

Recently Posted Jobs

Explore more opportunities at argenx

See more jobs